Pin your most used calculators here by clicking the star in the dropdown.
EBV-DNA Prognostic Score (NPC)
Clinical Context & Background
The integration of pre-treatment plasma Epstein-Barr Virus (EBV) DNA load with TNM staging significantly improves prognostic stratification in Nasopharyngeal Carcinoma (NPC). Patients with advanced stage but low EBV DNA often have survival rates comparable to earlier stages, while high EBV DNA identifies a high-risk subgroup requiring intensive therapy.
Formula Logic
Risk stratification based on Stage (I-IV) and EBV DNA cutoff (e.g., 4000 copies/mL).Reference Data
| Risk Group | Criteria | 3-Year Overall Survival |
|---|---|---|
| Very Low Risk | Stage I | > 98% |
| Low Risk | Stage II-IVA + Low EBV DNA | ~ 90% |
| Intermediate Risk | Stage II-III + High EBV DNA | ~ 80% |
| High Risk | Stage IVA + High EBV DNA | < 70% |
Popular Tools
Evidence-based oncology decision support. Verify with clinical guidelines.